Buy Parlodel (Bromocriptine 2.5mg) Online - Serum Pharmaceuticals Original Sandoz Brand Dopamine Agonist

Parlodel (Bromocriptine Mesylate 2.5 mg) represents the foundational first-generation ergot-derived dopamine agonist - the reference dopamine receptor agonist established over 45 years for hyperprolactinemia treatment, prolactinoma management, comprehensive fertility restoration, lactation suppression, Parkinson disease therapy, and acromegaly management. Originally developed by Sandoz Pharmaceuticals (now Novartis following the 1996 merger with Ciba-Geigy) and FDA-approved as Parlodel in 1978 for hyperprolactinemia and other prolactin-related disorders, bromocriptine established the pharmacological approach to dopamine agonist therapy across multiple therapeutic areas. Parlodel on rxshop.md is manufactured by Serum Pharmaceuticals with established quality manufacturing standards. Approved for hyperprolactinemia, prolactinomas, amenorrhea, galactorrhea, infertility from hyperprolactinemia, Parkinson disease, and acromegaly. This comprehensive medication guide covers ergot-derived dopamine agonist pharmacology, non-selective D2 mechanism, all approved indications, comprehensive dosing protocols with careful titration, CRITICAL cardiac valve fibrosis warnings, impulse control disorders monitoring, contraindications, drug interactions, and long-term therapy considerations across multiple therapeutic areas.

Serum Pharmaceuticals credentials:

• Established Indian pharmaceutical manufacturer with generic portfolio
• Focus on reproductive medicine, endocrinology, neurology therapeutic areas
• Quality manufacturing standards ensuring bioequivalent generic quality
• Cost-effective manufacturing enabling accessible dopamine agonist therapy pricing
• Regional and international distribution serving Indian and international markets
• Comprehensive gynecology and endocrinology product line
• Established portfolio in hormone therapy and specialty medications
• Bioequivalent generic quality supporting equivalent clinical effects

Dopamine agonist categories:

• Ergot-derived dopamine agonists: Bromocriptine (Parlodel), cabergoline (Dostinex), pergolide - derived from ergot alkaloid structure
• Non-ergot dopamine agonists: Pramipexole, ropinirole, rotigotine - modern class without ergot skeleton
• Selective D2 agonists: Cabergoline (highly selective), quinagolide
• Non-selective agonists: Bromocriptine (D2 primary with moderate D1), pergolide
• Short-acting: Bromocriptine (twice-daily dosing typical)
• Long-acting: Cabergoline (twice-weekly dosing possible)

Bromocriptine structural features:

• Ergoline core structure - characteristic tetracyclic ergot alkaloid backbone
• 2-bromination modification - key structural feature providing dopamine agonist activity
• Peptide side chain - cyclic tripeptide portion of ergocryptine structure
• Complex stereochemistry - multiple chiral centers
• Mesylate salt form - enhanced solubility and bioavailability
• Ergot alkaloid class - shared structural features with other ergot compounds
• Semi-synthetic derivative - modified natural ergocryptine backbone

Bromocriptine dopamine receptor activity:

• D2 dopamine receptor: Primary target - full agonist activity
• D1 dopamine receptor: Partial agonist to weak antagonist activity
• D3 dopamine receptor: Full agonist activity
• Serotonin 5-HT2A receptor: Partial agonist (contributes to fibrotic concerns)
• Alpha-adrenergic receptors: Weak activity contributing to orthostatic effects
• Non-selective profile: Multiple receptor activities vs cabergoline high D2 selectivity

Bromocriptine mechanism in hyperprolactinemia:

1. Pituitary lactotroph D2 receptor binding: Bromocriptine binds D2 receptors on pituitary lactotroph cells
2. Mimics dopamine inhibition: Acts like natural hypothalamic dopamine which normally inhibits prolactin secretion
3. Direct prolactin suppression: Immediate suppression of prolactin secretion from lactotroph cells
4. Prolactinoma cell effect: Direct suppression of prolactinoma tumor cells
5. Progressive tumor shrinkage: Weeks to months of tumor size reduction from cell size reduction and apoptosis
6. Restored HPG axis function: Prolactin normalization restores hypothalamic-pituitary-gonadal axis
7. Return of ovulation: Restored reproductive hormone patterns enable ovulation and menstruation

Prolactin physiology overview:

• Produced by pituitary lactotroph cells
• Uniquely regulated by dopamine INHIBITION (unlike other pituitary hormones stimulated by hypothalamic factors)
• Normal blood levels: Under 25 ng/mL in women, under 20 ng/mL in men
• Physiological elevations: Pregnancy, lactation, stress, sleep, exercise
• Primary function: Lactation initiation and maintenance after childbirth
• Additional roles: Reproductive function, immune modulation, osmoregulation
• Feedback: Elevated prolactin suppresses GnRH and downstream reproductive hormones

Parlodel most appropriate for:

1. Patients with confirmed hyperprolactinemia after appropriate diagnostic workup
2. Prolactinoma patients (medical therapy first-line for most cases)
3. Women with hyperprolactinemic amenorrhea, galactorrhea, or infertility
4. Women planning pregnancy where bromocriptine safety data preferred over cabergoline
5. Men with hyperprolactinemia causing sexual dysfunction or infertility
6. Patients preferring cost-effective dopamine agonist therapy
7. Patients intolerant to cabergoline requiring alternative dopamine agonist
8. Patients requiring postpartum lactation suppression (where clinically appropriate)
9. Selected Parkinson disease patients (usually non-ergot agents preferred)
10. Selected acromegaly patients responsive to dopamine agonist therapy
11. Patients able to accept 2-3 times daily dosing schedule
12. Patients without cardiac valve disease
13. Patients without fibrotic disorder history
14. Patients accepting endocrinology specialist supervision

• Uncontrolled hypertension
• Cardiac valvular disease - fibrotic or regurgitant valve disease
• Pulmonary fibrosis or pleural fibrosis history
• Retroperitoneal fibrosis history
• Pericardial fibrosis history
• Hypersensitivity to bromocriptine or any ergot alkaloid
• Pregnancy-related hypertensive disorders (preeclampsia, eclampsia) history
• Severe ischemic heart disease
• Peripheral vascular disorders
• Postpartum use in women with cardiovascular risk factors

CRITICAL: Cardiac Valve Fibrosis Warning

Ergot-derived dopamine agonists including bromocriptine have been associated with cardiac valve fibrosis particularly at higher doses used for Parkinson disease treatment. Risk at hyperprolactinemia doses (usually 2.5-15 mg daily) is substantially lower but ongoing monitoring is recommended.

Monitoring recommendations:

• Baseline echocardiogram before starting long-term therapy
• Periodic echocardiograms during extended therapy (every 1-2 years typical)
• Clinical monitoring: Dyspnea, chest pain, cardiovascular symptoms
• Discontinuation: If clinically significant valvular disease develops
• Higher doses (over 30 mg daily): More stringent monitoring recommended
• Risk lower than pergolide (removed from US market for this reason)

Impulse Control Disorders (Dopamine Agonist Class)

All dopamine agonists including bromocriptine carry risk of developing impulse control disorders. Patients and families should be informed and monitored throughout therapy.

Impulse control disorders to monitor:

• Pathological gambling
• Hypersexuality
• Compulsive shopping
• Binge eating
• Increased libido
• Other compulsive behaviors

Family members should be aware of warning signs. Discontinue if impulse control disorders develop - usually reversible after discontinuation.

Fibrotic Disorders Warning

Long-term ergot-derived dopamine agonist therapy carries small risk of fibrotic complications beyond cardiac valves:

• Pulmonary fibrosis: Progressive shortness of breath, dry cough
• Pleural fibrosis: Progressive dyspnea, chest pain
• Retroperitoneal fibrosis: Back pain, kidney dysfunction, edema
• Pericardial fibrosis: Chest pain, heart failure symptoms

Regular clinical monitoring during long-term therapy. Discontinue if fibrotic complications develop.

Postpartum Cardiovascular Warning:

Rare but serious postpartum cardiovascular events (stroke, myocardial infarction, seizure) reported with bromocriptine use for lactation suppression. Not FDA approved for this indication in US. Avoid postpartum use in women with cardiovascular risk factors, hypertension, preeclampsia/eclampsia history.

Standard bromocriptine titration:

• Starting dose: 1.25 mg (half tablet) at bedtime for first 3-7 days
• Take with food to minimize nausea
• Bedtime dosing initially to reduce postural hypotension
• Escalation: Increase by 1.25 mg every 3-7 days as tolerated
• Divide dosing: Once at 5 mg daily, split into 2-3 divided doses
• Reach maintenance dose: Individualized based on prolactin response and tolerability
• Standard hyperprolactinemia maintenance: 2.5-15 mg daily divided doses
• Parkinson disease: Higher doses needed - up to 30-40 mg daily divided doses
• Acromegaly: Higher doses needed - 20-40 mg daily divided doses

Nausea management strategies:

• Take with food: Reduces GI irritation
• Bedtime dosing initially: Sleep through peak nausea
• Start low, go slow: Gradual titration allows tolerance development
• Domperidone (not FDA-approved US): Peripheral dopamine antagonist for severe cases
• Nausea typically improves: After first few weeks of therapy
• Consider switch to cabergoline: If nausea persistent and intolerable

Seek immediate medical attention for:

• Signs of cardiac valve disease: Dyspnea, chest pain, palpitations
• Signs of pulmonary fibrosis: Progressive dyspnea, dry cough
• Signs of retroperitoneal fibrosis: Back pain, edema, kidney dysfunction
• Impulse control disorders: Gambling, hypersexuality, compulsive behaviors
• Severe postural hypotension: Syncope, falls
• Psychiatric symptoms: Psychosis, hallucinations, severe depression
• Severe allergic reactions: Angioedema, difficulty breathing
• Suspected pregnancy: Discuss continuation with prescriber
• Visual field changes: May indicate prolactinoma growth
• Severe headache with visual changes: Possible pituitary apoplexy
• Signs of stroke or MI (postpartum use): Emergency medical care

Bromocriptine pregnancy features:

• Category B classification - substantial pregnancy safety data
• Over 6000 documented pregnancy exposures without teratogenic effects
• Preferred over cabergoline when pregnancy is planned or desired
• Standard practice: Discontinue when pregnancy confirmed unless prolactinoma requires continuation
• Prolactinoma pregnancy management: Some macroprolactinoma patients continue bromocriptine during pregnancy
• MRI monitoring: During pregnancy for macroprolactinoma patients
• Fertility restoration timing: Rapid ovulation return - contraception needed if pregnancy not desired

Postpartum and lactation considerations:

• Suppresses lactation: Not compatible with breastfeeding
• Used for lactation suppression: In some countries (not FDA approved US)
• Postpartum cardiovascular risk: Avoid in women with cardiovascular risk factors
• Non-breastfeeding postpartum use: Standard indications apply
• Alternative therapies: Consider if breastfeeding desired

• Store at room temperature 15-25°C (59-77°F)
• Protect from light and moisture
• Keep tablets in original packaging
• Keep out of reach of children and pets
• Do not use past expiration date
• Do not share medication with others
• Return unused medication to pharmacy for proper disposal
• Store in dry area - avoid humid bathrooms

Essential points about Parlodel therapy:

• Parlodel is Serum Pharmaceuticals generic bromocriptine mesylate 2.5 mg tablets
• Original Sandoz brand FDA-approved 1978 (Sandoz merged with Ciba-Geigy to form Novartis 1996)
• Over 45 years continuous clinical use worldwide
• First-generation ergot-derived dopamine agonist
• 2-bromo-alpha-ergocryptine mesylate - semi-synthetic ergot alkaloid derivative
• Non-selective dopamine receptor agonism (D2 primary + moderate D1)
• Approved for hyperprolactinemia, prolactinomas, amenorrhea, galactorrhea, infertility from elevated prolactin
• Approved for Parkinson disease and acromegaly (paradoxical GH suppression)
• Bromocriptine PREFERRED over cabergoline when pregnancy is planned - extensive pregnancy safety data
• Standard hyperprolactinemia dosing: 2.5-15 mg daily divided doses
• Parkinson disease dosing: up to 30-40 mg daily divided doses
• CRITICAL titration protocol: start 1.25 mg at bedtime, escalate every 3-7 days
• Take with food to minimize nausea and improve absorption
• Prolactin normalization in 70-80 percent of patients
• Prolactinoma tumor shrinkage in 50-70 percent of patients
• Restores menstruation in over 80 percent of women
• CRITICAL: Cardiac valve fibrosis monitoring - baseline echocardiogram and periodic during therapy
• CRITICAL: Impulse control disorders - patient and family awareness essential
• CRITICAL: Fibrotic disorders - pulmonary, pericardial, retroperitoneal monitoring
• Contraindicated in cardiac valvular disease, fibrotic disorders, uncontrolled hypertension, ergot allergy
• Common nausea (up to 50 percent) manageable with food and gradual titration
• Postural hypotension particularly with first doses - bedtime dosing initially
• Long-term therapy typically required with periodic reassessment

Important Medical Disclaimer: This medication guide provides general information about Parlodel (Serum Pharmaceuticals generic bromocriptine mesylate 2.5 mg tablets) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by an endocrinologist, gynecologist, neurologist, or qualified healthcare provider before starting dopamine agonist therapy. Parlodel requires comprehensive workup to establish hyperprolactinemia cause including pituitary MRI, thyroid function testing, medication review, pregnancy testing, and cardiovascular assessment before initiation. Long-term therapy requires periodic prolactin monitoring, dose adjustments, and echocardiogram surveillance. Prolactinoma patients require regular pituitary MRI monitoring. CRITICAL SAFETY: Ergot-derived dopamine agonists including bromocriptine carry cardiac valve fibrosis risk requiring baseline and periodic echocardiogram monitoring during long-term therapy. Fibrotic complications including pulmonary, pericardial, and retroperitoneal fibrosis are rare but serious adverse events. Contraindicated in cardiac valvular disease, fibrotic disorders history (pulmonary, pericardial, retroperitoneal), uncontrolled hypertension, ergot alkaloid hypersensitivity, and pregnancy-related hypertensive disorders history. Dopamine agonist class carries impulse control disorder risk (pathological gambling, hypersexuality, compulsive behaviors) requiring patient and family awareness. CRITICAL titration protocol essential to minimize nausea and orthostatic hypotension - start 1.25 mg at bedtime, escalate every 3-7 days, take with food. Bromocriptine remains preferred dopamine agonist when pregnancy is planned due to extensive safety data. Postpartum use for lactation suppression rarely causes serious cardiovascular events - avoid in women with cardiovascular risk factors. Report cardiovascular symptoms, breathing difficulties, impulse control changes, severe postural hypotension, or psychiatric symptoms immediately. Not compatible with breastfeeding due to lactation suppression. Long-term therapy requires periodic reassessment. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your endocrinologist or neurologist.